BioSpace News Archive

Gilead's corporate headquarters in Silicon Valley

Gilead’s Trodelvy Shows Potential as First-Line Treatment in NSCLC

The first-in-class antibody-drug conjugate—in combination with Merck’s Keytruda—has shown promising results in a Phase II study of patients with metastatic non-small cell lung cancer.

September 11, 2023

·

2 min read

·

Tristan Manalac

Pictured: Test-tube containing a patient's sample

Drug Development

Crinetics Aces Phase III in Rare Disease Acromegaly with Once-Daily Pill

The California pharma is building up to its first-ever approval with promising late-stage data for its once-daily investigational acromegaly pill paltusotine, an alternative to the injectable standard of care.

September 11, 2023

·

2 min read

·

Tristan Manalac

Pictured: Facade of Moderna's building in Massachusetts

Business

Moderna, Immatics Ink Potential $1.8B Oncology Deal including Cancer Vaccines

The collaboration, which includes an upfront payment of $120 million to Immatics, pairs Moderna’s mRNA technology with Immatics’ T-cell receptor platform for cancer treatment.

September 11, 2023

·

2 min read

·

Connor Lynch

Pictured: Facade of Novartis building in Switzerland

Deals

Novartis Drops Eye Disease Gene Therapy from $800M Gyroscope Acquisition

Following a Phase II review, Novartis has cut the development of a gene therapy candidate for geographic atrophy. In June, the company sold a dry eye disease drug to Bauch + Lomb for $1.75 billion.

September 11, 2023

·

2 min read

·

Tristan Manalac

Pictured: Needle drawing up mRNA vaccine/iStock, D

FDA

Moderna, Pfizer-BioNTech’s Updated COVID-19 Vaccines Approved by FDA

The regulator Monday approved the companies’ supplemental Biologics License Applications for their respective mRNA shots formulated to more closely target currently circulating variants.

September 11, 2023

·

2 min read

·

Hayley Shasteen

Drug Development

Treatment with RYBREVANT® (amivantamab-vmjw) and Lazertinib Plus Chemotherapy Showed Durable Progression-Free Survival in Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced follow-up results from the Phase 1b/2 CHRYSALIS-2 study cohort evaluating the safety and tolerability of the combination of RYBREVANT®,

September 11, 2023

·

19 min read

Pharm Country

Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington’s Cancer Research Endowment

Coeptis Therapeutics Holdings, Inc. announced that Deverra Therapeutics, Inc. (“Deverra Therapeutics”) was selected by the Andy Hill CARE Fund, Washington’s Cancer Research Endowment, for two Life Science Start-Up and Development Awards.

September 11, 2023

·

6 min read

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11-13, 2022.

September 11, 2023

·

4 min read

Biotech Beach

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform

Cellares and Lyell Immunopharma announced Lyell will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership program.

September 11, 2023

·

8 min read

Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting

Achieve Life Sciences, Inc. (NASDAQ: ACHV) today announced that Phase 2 ORCA-V1 trial results will be presented at the Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting, being held in London September 11–13, 2023.

September 11, 2023

·

7 min read